# The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

> **NCT05208229** · — · TERMINATED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DIAGNOSTIC_TEST:** WB-MRI

## Key facts

- **NCT ID:** NCT05208229
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-01
- **Primary completion:** 2022-03-08
- **Final completion:** 2022-03-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was linked to another protocol that is over
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208229, "The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05208229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*